Healthcare Quality Expert Committee (HQ EC)
October 14, 2016
USP–U.S., Rockville, MD

Executive Summary

A quorum was present and Dr. Dennis Doherty, Chair, presided over the Healthcare Quality Expert Committee (HQ EC) face-to-face meeting. The following is a summary of the actions and key discussion topics that impacted the work of the HQ EC, grouped by topic.

1. **Medicare Model Guidelines (MMG) Subcommittee:** The MMG v.7.0 was posted on USP.org for public comment from October 3, 2016, to November 2, 2016. Stakeholders may also provide feedback at open microphone Web meetings October 17, 19, and 20, 2016.

2. **Model Guidelines for All U.S. Marketed Products Expert Panel (AMPEP):** The EC changed the name of the "Model Guidelines for All U.S. Marketed Products" to "USP Drug Classification System" ("USP DC") and approved the USP DC 2017 Guiding Principles. The USP DC will be posted for public comment on USP.org from November 1, 2016, to December 5, 2016. Stakeholders may provide feedback at open microphone Web meetings to be held November 8 and 9, 2016.

3. **New Opioid/Naloxone Subcommittee:** The EC formed this new Subcommittee to discuss potential USP approaches to address opioid and Naloxone issues and provide recommendations to the EC.

4. **Parenteral Nutrition Safety Expert Panel:** This Expert Panel is developing a proposed new parenteral nutrition safety general chapter numbered under 1000 and a related Stimuli article.

5. **Safety Subcommittee:** This Subcommittee discussed the Institute for Safe Medication Practices (ISMP) safety alerts on the following:

   Labeling of Electrolytes on Large Volume Parenterals (LVPs): Concentrations are listed per liter, not per container volume on LVPs, and this has caused medication errors. The HQ EC will ask the Nomenclature and Labeling (NL) EC to address the presentation of electrolytes in the labeling of LVPs.

   Two Component Vaccines: Some products have components with different storage requirements (e.g., one component requires refrigeration and the other does not). A two-component vaccine was involved in errors when only one part was administered to patients. The HQ EC will ask the General Chapters–Packaging and Distribution (GCPD) EC to consider the packaging of two-component products with one storage temperature or two storage temperatures.

   Fluzone Vaccine Labeling: High-Dose Fluzone product labeling could lead to medication errors. The Safety Subcommittee will consider Fluzone Vaccine labeling issues and provide recommendations to the EC.

6. **Drug Allergy and Intolerance Classification Expert Panel:** This Expert Panel is developing an interoperable Drug Allergy and Intolerance Initial Value Set. It will use recognized guidance to create classifications of index-challenge substance pairs that are mapped to common clinical manifestations.

7. **Health Literacy Expert Panel:** USP is continuing to work with the U.S. Centers for Disease Control and Prevention Protect initiative to prevent overdoses in children under age 6. Wisconsin asked USP to be part of its advisory council to pilot a patient-centered label.